Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1987 2
1988 8
1989 7
1990 16
1991 7
1992 10
1993 16
1994 9
1995 10
1996 14
1997 11
1998 11
1999 8
2000 14
2001 15
2002 13
2003 18
2004 16
2005 24
2006 23
2007 28
2008 19
2009 18
2010 20
2011 14
2012 24
2013 34
2014 43
2015 63
2016 66
2017 93
2018 72
2019 62
2020 77
2021 88
2022 101
2023 101
2024 43

Text availability

Article attribute

Article type

Publication date

Search Results

1,094 results

Results by year

Filters applied: . Clear all
Page 1
Cystic Lung Diseases: Algorithmic Approach.
Raoof S, Bondalapati P, Vydyula R, Ryu JH, Gupta N, Raoof S, Galvin J, Rosen MJ, Lynch D, Travis W, Mehta S, Lazzaro R, Naidich D. Raoof S, et al. Chest. 2016 Oct;150(4):945-965. doi: 10.1016/j.chest.2016.04.026. Epub 2016 May 13. Chest. 2016. PMID: 27180915 Free PMC article. Review.
Cysts that are present in the lung parenchyma but away from subpleural areas may be present without any other abnormalities on high-resolution CT scans. ...Multifocal/diffuse cysts may be associated with nodules (lymphoid interstitial pneumonia, light-chain depositi …
Cysts that are present in the lung parenchyma but away from subpleural areas may be present without any other abnormalities on high-r …
Smoking-Related Interstitial Lung Diseases.
Alarcon-Calderon A, Vassallo R, Yi ES, Ryu JH. Alarcon-Calderon A, et al. Immunol Allergy Clin North Am. 2023 May;43(2):273-287. doi: 10.1016/j.iac.2023.01.007. Epub 2023 Mar 1. Immunol Allergy Clin North Am. 2023. PMID: 37055089 Review.
Smoking-related interstitial lung diseases (ILDs) are a group of heterogeneous, diffuse pulmonary parenchymal disease processes associated with tobacco exposure. ...This review summarizes the current evidence of pathogenesis, clinical manifestations, d …
Smoking-related interstitial lung diseases (ILDs) are a group of heterogeneous, diffuse pulmonary parenchymal diseas
Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs).
Spagnolo P, Distler O, Ryerson CJ, Tzouvelekis A, Lee JS, Bonella F, Bouros D, Hoffmann-Vold AM, Crestani B, Matteson EL. Spagnolo P, et al. Ann Rheum Dis. 2021 Feb;80(2):143-150. doi: 10.1136/annrheumdis-2020-217230. Epub 2020 Oct 9. Ann Rheum Dis. 2021. PMID: 33037004 Free PMC article. Review.
Interstitial lung diseases (ILDs), which can arise from a broad spectrum of distinct aetiologies, can manifest as a pulmonary complication of an underlying autoimmune and connective tissue disease (CTD-ILD), such as rheumatoid arthritis-ILD and systemi
Interstitial lung diseases (ILDs), which can arise from a broad spectrum of distinct aetiologies, can manifest as a pul
Lung involvement in ANCA-associated vasculitis.
Sacoto G, Boukhlal S, Specks U, Flores-Suárez LF, Cornec D. Sacoto G, et al. Presse Med. 2020 Oct;49(3):104039. doi: 10.1016/j.lpm.2020.104039. Epub 2020 Jul 7. Presse Med. 2020. PMID: 32650042 Review.
Lung involvement is one of the most common clinical features in ANCA-associated vasculitides (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). In this review, we detail the fiv
Lung involvement is one of the most common clinical features in ANCA-associated vasculitides (AAV), including granulomatosis with pol
Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.
Rahaghi FF, Hsu VM, Kaner RJ, Mayes MD, Rosas IO, Saggar R, Steen VD, Strek ME, Bernstein EJ, Bhatt N, Castelino FV, Chung L, Domsic RT, Flaherty KR, Gupta N, Kahaleh B, Martinez FJ, Morrow LE, Moua T, Patel N, Shlobin OA, Southern BD, Volkmann ER, Khanna D. Rahaghi FF, et al. Respir Res. 2023 Jan 9;24(1):6. doi: 10.1186/s12931-022-02292-3. Respir Res. 2023. PMID: 36624431 Free PMC article.
BACKGROUND: Systemic sclerosis (SSc) is a rare, complex, connective tissue disorder. Interstitial lung disease (ILD) is common in SSc, occurring in 35-52% of patients and accounting for 20-40% of mortality. ...Concomitant use of nintedanib with MMF/cyclophosp …
BACKGROUND: Systemic sclerosis (SSc) is a rare, complex, connective tissue disorder. Interstitial lung disease (ILD) is …
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management.
Swain SM, Nishino M, Lancaster LH, Li BT, Nicholson AG, Bartholmai BJ, Naidoo J, Schumacher-Wulf E, Shitara K, Tsurutani J, Conte P, Kato T, Andre F, Powell CA. Swain SM, et al. Cancer Treat Rev. 2022 May;106:102378. doi: 10.1016/j.ctrv.2022.102378. Epub 2022 Mar 12. Cancer Treat Rev. 2022. PMID: 35430509 Free article. Review.
SEARCH STRATEGY AND SELECTION CRITERIA: References were identified based on the guidelines used by the authors in treating interstitial lung disease and pneumonitis. Searches of the authors' own files were also completed. A search of PubMed with the search te …
SEARCH STRATEGY AND SELECTION CRITERIA: References were identified based on the guidelines used by the authors in treating interstitial
Treatment Outcomes for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Real-World, Multisite Study of the Impact of Immunosuppression on Pulmonary Function Trajectory.
Matson SM, Baqir M, Moua T, Marll M, Kent J, Iannazzo NS, Boente RD, Donatelli JM, Dai J, Diaz FJ, Demoruelle MK, Hamblin MB, Mathai SK, Ryu JH, Pope K, Walker CM, Lee JS. Matson SM, et al. Chest. 2023 Apr;163(4):861-869. doi: 10.1016/j.chest.2022.11.035. Epub 2022 Dec 5. Chest. 2023. PMID: 36470416 Free PMC article. Clinical Trial.
BACKGROUND: Rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) is common in patients with RA and leads to significant morbidity and mortality. ...STUDY DESIGN AND METHODS: Patients with RA who started treatment for ILD with mycophenolate, az …
BACKGROUND: Rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) is common in patients with RA and lead …
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M; INBUILD trial investigators. Wells AU, et al. Lancet Respir Med. 2020 May;8(5):453-460. doi: 10.1016/S2213-2600(20)30036-9. Epub 2020 Mar 5. Lancet Respir Med. 2020. PMID: 32145830 Clinical Trial.
BACKGROUND: The INBUILD trial investigated the efficacy and safety of nintedanib versus placebo in patients with progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF). ...Of 663 participants who received at lea …
BACKGROUND: The INBUILD trial investigated the efficacy and safety of nintedanib versus placebo in patients with progressive fibrosing in
International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults.
Goyal G, Tazi A, Go RS, Rech KL, Picarsic JL, Vassallo R, Young JR, Cox CW, Van Laar J, Hermiston ML, Cao XX, Makras P, Kaltsas G, Haroche J, Collin M, McClain KL, Diamond EL, Girschikofsky M. Goyal G, et al. Blood. 2022 Apr 28;139(17):2601-2621. doi: 10.1182/blood.2021014343. Blood. 2022. PMID: 35271698 Free PMC article.
Langerhans cell histiocytosis (LCH) can affect children and adults with a wide variety of clinical manifestations, including unifocal, single-system multifocal, single-system pulmonary (smoking-associated), or multisystem disease. The existing paradigms in the management o …
Langerhans cell histiocytosis (LCH) can affect children and adults with a wide variety of clinical manifestations, including unifocal, singl …
Methotrexate and rheumatoid arthritis associated interstitial lung disease.
Juge PA, Lee JS, Lau J, Kawano-Dourado L, Rojas Serrano J, Sebastiani M, Koduri G, Matteson E, Bonfiglioli K, Sawamura M, Kairalla R, Cavagna L, Bozzalla Cassione E, Manfredi A, Mejia M, Rodríguez-Henriquez P, González-Pérez MI, Falfán-Valencia R, Buendia-Roldán I, Pérez-Rubio G, Ebstein E, Gazal S, Borie R, Ottaviani S, Kannengiesser C, Wallaert B, Uzunhan Y, Nunes H, Valeyre D, Saidenberg-Kermanac'h N, Boissier MC, Wemeau-Stervinou L, Flipo RM, Marchand-Adam S, Richette P, Allanore Y, Dromer C, Truchetet ME, Richez C, Schaeverbeke T, Lioté H, Thabut G, Deane KD, Solomon JJ, Doyle T, Ryu JH, Rosas I, Holers VM, Boileau C, Debray MP, Porcher R, Schwartz DA, Vassallo R, Crestani B, Dieudé P. Juge PA, et al. Eur Respir J. 2021 Feb 11;57(2):2000337. doi: 10.1183/13993003.00337-2020. Print 2021 Feb. Eur Respir J. 2021. PMID: 32646919 Free PMC article.
QUESTION ADDRESSED BY THE STUDY: Methotrexate (MTX) is a key anchor drug for rheumatoid arthritis (RA) management. Fibrotic interstitial lung disease (ILD) is a common complication of RA. Whether MTX exposure increases the risk of ILD in patients with RA is d …
QUESTION ADDRESSED BY THE STUDY: Methotrexate (MTX) is a key anchor drug for rheumatoid arthritis (RA) management. Fibrotic interstitial
1,094 results